STAT+: Atlas Venture launches another biotech to tackle vision loss

Call it “Quest for Sight: The Sequel.”

In September, the Swiss drug giant Novartis paid $150 million for a Cambridge startup that had developed a pair of potential gene therapies to restore vision to people with blindness stemming from genetic diseases. It was a sizable return for the biotech, which had used roughly half of the $21 million in venture capital it had raised after its founding about 17 months earlier by Atlas Venture.

Continue to STAT+ to read the full story…

Read Original Article: STAT+: Atlas Venture launches another biotech to tackle vision loss »